Have a Claim?

Click here for a confidential contact or call:

1-212-350-2764

November 7, 2019

Posted  November 7, 2019

Compound drug ingredient supplier Fagron Holding USA LLC has agreed to pay over $22 million to resolve two qui tam suits involving three of Fagron’s wholly-owned subsidiaries.  According to whistleblowers, Freedom Pharmaceuticals Inc. grossly inflated the price of active pharmaceutical ingredients used in compound prescriptions, causing pharmacy customers to submit false claims to TRICARE.  Other allegations involved subsidiaries Pharmacy Services Inc. and B&B Pharmaceuticals Inc., which were accused of submitting false claims to federal healthcare programs, manipulating prescription drug pricing, paying kickbacks to physicians, and illegally waiving patient copays.  DOJ

Tagged in: Compounding Pharmacy Fraud, Drug and DME Pricing, FCA Federal, Other Government Health Programs, Pharma Fraud, Whistleblower Case, Whistleblower Rewards,

Newsletter

Subscribe to receive email updates from the Constantine Cannon blogs

Sign up for: